$10.1B 14.7% 1
SALES WORLDWIDE MEDICAL DEVICES

$1.142 10.1%
ADJUSTED DILuted EPS DIAGNOSTICS

RAISING MIDPOINT OF FULL-YEAR EPS GUIDANCE RANGE
$4.42 to $4.463
Adjusted Diluted EPS

KEY BUSINESS UNITS4 ORGANIC* SALES GROWTH FOR UNDERLYING BASE BUSINESS**

14.7% MEDICAL DEVICES
10.1% DIAGNOSTICS
11.1% ESTABLISHED PHARMACEUTICALS
18.1% NUTRITION

MORE PEOPLE USING CGM AND GLP-1 DRUGS TOGETHER

> Newly published Abbott analysis shows growing number of people are using Abbott’s FreeStyle Libre*** continuous glucose monitoring systems and GLP-1 medications together.

> Abbott analysis also shows these complementary tools help support behavior change, diabetes treatment and overall health.

COMPLETED ACQUISITION OF BIGFOOT BIOMEDICAL

> Expands development of personalized solutions for diabetes management.

> Builds on Abbott’s world-leading FreeStyle Libre portfolio of continuous glucose monitoring systems.

BROADENING EMERGING MARKET ACCESS TO CUTTING-EDGE MEDICINES

> Expanded existing collaboration with global biotech leader mAbxience Holdings S.L.

> Abbott will commercialize several biosimilar molecules, with the goal of broadening access to these therapies for people in emerging markets.

RAISING MIDPOINT OF FULL-YEAR EPS GUIDANCE RANGE

$4.42 to $4.463
Adjusted Diluted EPS


2 Excludes the impact of COVID-19 testing sales.

3 Find important safety information about the FreeStyle Libre portfolio: www.freestylelibre.us/safety-information.

4 Forward-looking statements Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.